An Old Race Horse with Ligament Injury Cured by Stem Cell Therapy

RNL Bio CO LTD successfully treated an old horse that was suffering from ligament injury by stem cell therapy.
By: RNL Biostar, Inc
Spread the Word
Listed Under

* Horse
* Arthritis
* Ligament
* Stem Cell

* Health
* Pets
* Medical

* Rockville - Maryland - US

March 28, 2008 - PRLog -- RNL Bio. CO. LTD., announced that twenty two year old race horse from Samsung Equestrian Team, was successfully cured with stem cells isolated his own fat. He was suffering from ligament injury and has so far received three injections of stem cells. The first treatment started on Dec 18, 2007. The last stem cell injection was done in January 29. It is known rare that such an old horse could be successfully treated with stem cells.

Stem cell was processed and prepared in RNL Bio. On Nov 22 last year, 20g of fat was taken from his own body. Scientists at the firm purified stem cells from fat and cultured them to an appropriate amount. Stem cells packed within syringes were delivered to the vet for local injection into the joints. Ultrasound evaluation revealed marked healing and regeneration of the affected lesion.

Dr. Jeong Chan Ra, CEO of the firm said “The patient horse is 22 years old and is comparable to eighties of human age. It was very difficult to purify and expand stem cells from the aged tissue. Preservation of stem cells is recommended when animals are young and healthy.”

RNL Bio has already been providing stem cell therapies for kidney failure and osteoarthritis for veterinarians in South Korea. Such procedures can also facilitate the development of stem cell therapeutics for human diseases. The firm plans to develop human trial of stem cell therapy for arthritis in the near future.

About RNL Bio Co Ltd.

RNL Bio is a premier biotechnology company in Korea focused on stem cell therapeutics and life sciences technologies. Headquartered in Seoul with a recently opened state-of-the-art GMP facility, RNL is a publicly traded company on the Korean Stock Exchange (Code 003190) and strives to become a global leader in the development of stem cell therapeutics. In 2006 RNL established wholly owned US subsidiary, RNL Biostar, for clinical development in the US and for licensing its technologies in North and South America.

Email:Contact Author
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Most Viewed
Daily News

Like PRLog?
Click to Share